References
- Harb H, Chatila TA. Mechanisms of dupilumab. Clin Exp Allergy [Internet]. 2020;50:5–14. Available at. https://onlinelibrary.wiley.com/doi/10.1111/cea.13491
- Castro M, Corren J, Pavord ID, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med [Internet]. 2018;378:2486–2496. Available at. http://www.nejm.org/doi/10.1056/NEJMoa1804092
- Rabe KF, Nair P, Brusselle G, et al. Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med [Internet]. 2018;378:2475–2485. Available at. http://www.nejm.org/doi/10.1056/NEJMoa1804093
- Thaçi D, Simpson EL, Beck LA, et al. Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial. Lancet [Internet]. 2016;387:40–52. Available at. https://linkinghub.elsevier.com/retrieve/pii/S0140673615003888
- Blauvelt A, de Bruin-Weller M, Gooderham M, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet Internet]. 2017;389:2287–2303. Available at. https://linkinghub.elsevier.com/retrieve/pii/S0140673617311911
- Simpson EL, Bieber T, Guttman-Yassky E, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med [Internet]. 2016;375:2335–2348. Available at. http://www.nejm.org/doi/10.1056/NEJMoa1610020
- Bachert C, Han JK, Desrosiers M, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet. 2019;394:1638–1650. [Internet].
- Bachert C, Mannent L, Naclerio RM, et al. Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis. JAMA [Internet]. 2016;315:469. Available at. http://jama.jamanetwork.com/article.aspx?doi=10.1001/jama.2015.19330
- European Medicines Agency (EMA). Dupixent: EPAR - product information [Internet]. 2021. Available at: https://www.ema.europa.eu/en/documents/product-information/dupixent-epar-product-information_en.pdf.
- Wechsler ME, Ford LB, Maspero JF, et al. Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study. Lancet Respir Med [Internet]. 2021; Available at: https://linkinghub.elsevier.com/retrieve/pii/S2213260021003222.
- Campisi R, Crimi C, Nolasco S, et al. Real-World experience with dupilumab in severe asthma: one-year data from an Italian named patient program. J Asthma Allergy [Internet]. 2021;Vol 14:575–583. Available at. https://www.dovepress.com/real-world-experience-with-dupilumab-in-severe-asthma-one-year-data-fr-peer-reviewed-fulltext-article-JAA
- Dupin C, Belhadi D, Guilleminault L, et al. Effectiveness and safety of dupilumab for the treatment of severe asthma in a real‐life French multi‐centre adult cohort. Clin Exp Allergy. Internet]. 2020;50:789–798. Available at. https://onlinelibrary.wiley.com/doi/10.1111/cea.13614
- Renner A, Marth K, Patocka K, et al. Dupilumab rapidly improves asthma control in predominantly anti‐IL5/IL5R pretreated Austrian real‐life severe asthmatics. Immun Inflamm Dis [Internet]. 2021;9:624–627. Available at. https://onlinelibrary.wiley.com/doi/10.1002/iid3.434
- Ferrucci S, Casazza G, Angileri L, et al. Clinical response and quality of life in patients with severe atopic dermatitis treated with dupilumab: a single-center real-life experience. J Clin Med [Internet]. 2020;9:791. Available at. https://www.mdpi.com/2077-0383/9/3/791
- Marcant P, Balayé P, Merhi R, et al. Dupilumab-associated hypereosinophilia in patients treated for moderate-to-severe atopic dermatitis. J Eur Acad Dermatol Venereol. 2021;35:e394–e396.
- Patruno C, Napolitano M, Argenziano G, et al. Dupilumab therapy of atopic dermatitis of the elderly: a multicentre, real‐life study. J Eur Acad Dermatol Venereol [Internet]. 2021;35:958–964. Available at. https://onlinelibrary.wiley.com/doi/10.1111/jdv.17094
- Fargnoli MC, Esposito M, Ferrucci S, et al. Real-life experience on effectiveness and safety of dupilumab in adult patients with moderate-to-severe atopic dermatitis. J Dermatolog Treat. 2021;32:507–513. [Internet].
- Faiz S, Giovannelli J, Podevin C, et al. Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort. J Am Acad Dermatol. 2019;81:143–151.
- Eger K, Pet L, Weersink EJM, et al. Complications of switching from anti–IL-5 or anti–IL-5R to dupilumab in corticosteroid-dependent severe asthma. J Allergy Clin Immunol Pract. 2021;9:2913–2915. [Internet].
- Lommatzsch M, Stoll P, Winkler J, et al. Eosinophilic pleural effusion and stroke with cutaneous vasculitis: two cases of dupilumab-induced hypereosinophilia. Allergy Eur J Allergy Clin Immunol. 2021;76:2920–2923.
- Descamps V, Deschamps L, El Khalifa J, et al. Eosinophilic vasculitis associated with persistent dupilumab-induced hypereosinophilia in severe asthma. Respir Med Res. 2021;79:2019–2022.
- Briegel I, Felicio-Briegel A, Mertsch P, et al. Hypereosinophilia with systemic manifestations under dupilumab and possibility of dual benralizumab and dupilumab therapy in patients with asthma and CRSwNP. J Allergy Clin Immunol Pract [Internet]. 2021;12–14.
- Kimura A, Takeda A, Ikebukuro T, et al. Serum IgE reduction and paradoxical eosinophilia associated with allergic conjunctivitis after dupilumab therapy. J Ophthalmic Inflamm Infect. 2021;11:0–3.
- Ahn J, Bae JY, Seo SJ. A retrospective case series hypereosinophilia during dupilumab treatment: hypereosinophilia could be a pharmacogenetic biomarker of dupilumab. Dermatol Ther [Internet]. 2020;33:2–3. Available at. https://onlinelibrary.wiley.com/doi/10.1111/dth.13847
- Benzecry V, Pravettoni V, Segatto G, et al. Type 2 inflammation: atopic dermatitis, asthma, and hypereosinophilia successfully treated with dupilumab. J Investig Allergol Clin Immunol Internet]. 2021;31:261–263. Available at. http://www.jiaci.org/summary/vol31-issue3-num2266
- Wollenberg A, Beck LA, Blauvelt A, et al. Laboratory safety of dupilumab in moderate‐to‐severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS). Br J Dermatol [Internet]. 2020;182:1120–1135. Available at. https://onlinelibrary.wiley.com/doi/10.1111/bjd.18434
- Yamamoto H, Nagata M, Sakamoto Y. CC chemokines and transmigration of eosinophils in the presence of vascular cell adhesion molecule 1. Ann Allergy, Asthma Immunol. 2005;94:292–300. [Internet].
- Schleimer RP, Sterbinsky SA, Kaiser J, et al. IL-4 induces adherence of human eosinophils and basophils but not neutrophils to endothelium. Association with expression of VCAM-1. J Immunol [Internet]. 1992;148:1086–1092. Available at. http://www.ncbi.nlm.nih.gov/pubmed/1371130
- Doran E, Cai F, Holweg CTJ, et al. Interleukin-13 in asthma and other eosinophilic disorders. Front Med [Internet]. 2017;4. Available at.;. http://journal.frontiersin.org/article/10.3389/fmed.2017.00139/full
- Le Floc’h A, Allinne J, Nagashima K, et al. Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4Rα antibody, is required to broadly inhibit type 2 inflammation. Allergy. 2020;75:1188–1204.
- Guttman-Yassky E, Bissonnette R, Ungar B, et al. Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis. J Allergy Clin Immunol. 2019;143:155–172.
- Hamilton JD, Suárez-Fariñas M, Dhingra N, et al. Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis. J Allergy Clin Immunol. 2014;134:1293–1300.
- Rothenberg ME, Hogan SP. THE EOSINOPHIL. Annu Rev Immunol [Internet]. 2006;24:147–174. Available at. http://www.annualreviews.org/doi/10.1146/annurev.immunol.24.021605.090720
- Riaz N, Wolden SL, Gelblum DY, et al. Eosinophils in mucosal immune responses. Mucosal Immunol. 2016;118:6072–6078.
- Butt NM, Lambert J, Ali S, et al. Guideline for the investigation and management of eosinophilia. Br J Haematol [Internet]. 2017;176:553–572. Available at. http://www.ncbi.nlm.nih.gov/pubmed/28112388
- Olivieri B, Tinazzi E, Caminati M, et al. Biologics for the treatment of allergic conditions: eosinophil disorders. Immunol Allergy Clin North Am. 2020. DOI:10.1016/j.iac.2020.07.001.
- Sharma SK. Eosinophilia: rare cause of arterial thrombosis and cardioembolic stroke in childhood. World J Cardiol [Internet]. 2012;4:128. Available at. http://www.wjgnet.com/1949-8462/full/v4/i4/128.htm
- Munoz J, Hanbali A. Reactive eosinophilia and thrombosis. Blood [Internet]. 2012;120:27852785. Available at. 27852785. Available at. https://ashpublications.org/blood/article/120/14/2785/30504/Reactive-eosinophilia-and-thrombosis
- Nieto Roca L, Tomás-Mallebrera M, Martínez-Milla J, et al. Eosinophilic myocarditis: an uncommon aetiology. Eur Heart J [Internet]. 2020;41:3019–3020. Available at. https://academic.oup.com/eurheartj/article/41/31/3019/5825475
- Ginsberg F, Parrillo JE. Eosinophilic myocarditis. Heart Fail Clin [Internet]. 2005;1:419–429. Available at. https://linkinghub.elsevier.com/retrieve/pii/S1551713605000450
- Leru PM. Eosinophilic disorders: evaluation of current classification and diagnostic criteria, proposal of a practical diagnostic algorithm. Clin Transl Allergy [Internet]. 2019;9(36). 1–9.
- Akuthota P, Weller PF. Spectrum of eosinophilic end-organ manifestations. Immunol Allergy Clin North Am. [Internet]. 2015;35:403–411. Available at. https://linkinghub.elsevier.com/retrieve/pii/S0889856115000296
- Pizzolo F, Castagna A, Olivieri O, et al. Basophil blood cell count is associated with enhanced factor II plasma coagulant activity and increased risk of mortality in patients with stable coronary artery disease: not only neutrophils as prognostic marker in ischemic heart disease. J Am Heart Assoc [Internet]. 2021;10:1–27. Available at. https://www.ahajournals.org/doi/10.1161/JAHA.120.018243
- Gudbjartsson DF, Bjornsdottir US, Halapi E, et al. Sequence variants affecting eosinophil numbers associate with asthma and myocardial infarction. Nat Genet [Internet]. 2009;41:342–347. Available at. http://www.nature.com/articles/ng.323
- Madjid M, Fatemi O. Components of the complete blood count as risk predictors for coronary heart disease: in-depth review and update. Texas Hear Inst J [Internet]. 2013;40:17–29. Available at. http://www.ncbi.nlm.nih.gov/pubmed/23467296
- Kuang FL. Approach to patients with eosinophilia. Med Clin North Am [Internet]. 2020;104:1–14. Available at. https://linkinghub.elsevier.com/retrieve/pii/S0025712519300811
- Chen YK, Khoury P, Ware JM, et al. Marked and persistent eosinophilia in the absence of clinical manifestations. J Allergy Clin Immunol [Internet]. 2014;133:1195–1202.e2.
- Helbig G, Hus M, Francuz T. Characteristics and clinical outcome of patients with hypereosinophilia of undetermined significance. Med Oncol. 2014;1–5.
- Bjerrum OW, Siersma V, Hasselbalch HC, et al. Association of the blood eosinophil count with end-organ symptoms. Ann Med Surg [Internet]. 2019;45:11–18.
- Shomali W, Gotlib J. World health organization‐defined eosinophilic disorders: 2019 update on diagnosis, risk stratification, and management. Am J Hematol [Internet]. 2019;94:1149–1167. Available at. https://onlinelibrary.wiley.com/doi/10.1002/ajh.25617
- Kahn JE, Groh M, Lefèvre G. (A critical appraisal of) classification of hypereosinophilic disorders. Front Med [Internet]. 2017;4:1–6. Available at. http://journal.frontiersin.org/article/10.3389/fmed.2017.00216/full
- Mustin DE, Cole EF, Blalock TW, et al. Dupilumab-induced erythema nodosum. JAAD Case Rep. 2021 Nov 17;19:41–43. PMID: 34917722; PMCID: PMC8669247.
- Hilderink JM, Klinkenberg LJJ, Aakre KM, et al. Within-day biological variation and hour-to-hour reference change values for hematological parameters. Clin Chem Lab Med [Internet]. 2017;55:1013–1024. Available at. https://www.degruyter.com/document/doi/10.1515/cclm-2016-0716/html